Sandbox: manpreet kaur: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 45: | Line 45: | ||
* Amoxicillin(1gm) | * Amoxicillin(1gm) | ||
* Nitroimidazole(500mg) | * Nitroimidazole(500mg) | ||
| | |BID | ||
| | |||
| | BID | ||
BID | |||
BID or TID | |||
|10-14 | |||
|NO | |||
|- | |- | ||
|Rifabutin triple | |||
| | | | ||
* PPI(standard dose) | |||
* Rifabutin(300mg | |||
| | | | ||
| | | | ||
Revision as of 19:18, 27 October 2017
| Salvage therapies for Helicobacter pylori infection | ||||
|---|---|---|---|---|
| Regimen | Drugs(doses) | Dosing frequency | Duration(days) | FDA approval |
| Bismuth quadruple |
|
BID
QID QID TID or QID |
14 | NO(a) |
| Levofloxacin triple |
|
BID
QD BID |
14 | NO |
| Concomitant |
|
BID
BID BID BID or TID |
10-14 | NO |
| Rifabutin triple |
|
|||
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
References
- References should be cited for the material that you have put on your page. Type in {{reflist|2}}.This will generate your references in small font, in two columns, with links to the original article and abstract.
- For information on how to add references into your page, click here.